DealsNov 4, 2026, 05:32 PM
Quoin Pharmaceuticals Agrees to At-the-Market Offering with Leerink Partners
AI Summary
Quoin Pharmaceuticals Ltd. has entered into a sales agreement with Leerink Partners LLC, enabling the company to sell its American Depositary Shares (ADSs) through 'at the market offerings'. Leerink Partners will act as the sales agent, receiving a 3.0% commission on gross sale proceeds. The agreement allows for the suspension or termination of the offering by either party. The ADSs will be offered under the company's effective Registration Statement on Form S-3.
Key Highlights
- Quoin Pharmaceuticals entered into a sales agreement with Leerink Partners LLC.
- The agreement allows Quoin to sell American Depositary Shares (ADSs) through Leerink Partners.
- Sales will be conducted as 'at the market offerings' on Nasdaq or other trading markets.
- Leerink Partners will receive 3.0% of gross sale proceeds as compensation.
- Both parties have the right to suspend or terminate the agreement with proper notice.
Price Impact
More from QNRX